Vincerx Pharma, Inc.
VINC · NASDAQ
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Market Cap | $3 | $28 | $80 | $85 |
| - Cash | $4 | $5 | $3 | $8 |
| + Debt | $0 | $0 | $2 | $2 |
| Enterprise Value | -$2 | $23 | $78 | $79 |
| Revenue | $0 | $1 | $0 | $0 |
| % Growth | -100% | – | – | – |
| Gross Profit | $0 | $1 | $0 | -$0 |
| % Margin | – | 50% | – | – |
| EBITDA | -$3 | -$9 | -$8 | -$7 |
| % Margin | – | -800.1% | – | – |
| Net Income | -$5 | -$8 | -$8 | -$2 |
| % Margin | – | -748.5% | – | – |
| EPS Diluted | -0.96 | 4.22 | -1.41 | -0.32 |
| % Growth | -122.7% | 399.3% | -340.6% | – |
| Operating Cash Flow | -$4 | -$6 | -$6 | -$6 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$4 | -$6 | -$6 | -$6 |